BidaskClub downgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a buy rating to a hold rating in a report issued on Monday.

Other research analysts have also issued research reports about the company. Zacks Investment Research upgraded Fresenius Medical Care Corporation from a hold rating to a buy rating and set a $49.00 price objective for the company in a research report on Tuesday, April 25th. DZ Bank AG restated a neutral rating on shares of Fresenius Medical Care Corporation in a research report on Saturday, May 20th. Nord/LB restated a buy rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, June 28th. Royal Bank Of Canada restated a neutral rating on shares of Fresenius Medical Care Corporation in a research report on Wednesday, May 3rd. Finally, UBS AG restated a sell rating on shares of Fresenius Medical Care Corporation in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $48.67.

Fresenius Medical Care Corporation (NYSE FMS) traded up 0.37% on Monday, reaching $46.28. 157,096 shares of the company traded hands. The stock has a 50 day moving average of $48.44 and a 200-day moving average of $44.54. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22. The stock has a market capitalization of $28.50 billion, a price-to-earnings ratio of 22.80 and a beta of 0.47.

Fresenius Medical Care Corporation (NYSE:FMS) last issued its earnings results on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.53 by $0.05. The firm had revenue of $4.47 billion during the quarter, compared to analyst estimates of $5.20 billion. Fresenius Medical Care Corporation had a return on equity of 11.62% and a net margin of 7.06%. Fresenius Medical Care Corporation’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.96 EPS. On average, equities analysts anticipate that Fresenius Medical Care Corporation will post $2.32 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/03/fresenius-medical-care-corporation-nysefms-downgraded-by-bidaskclub.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Asset Management Americas Inc. purchased a new position in Fresenius Medical Care Corporation during the fourth quarter worth $1,133,000. Quadrant Capital Group LLC raised its position in Fresenius Medical Care Corporation by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock worth $149,000 after buying an additional 420 shares during the last quarter. LLBH Private Wealth Management LLC purchased a new position in Fresenius Medical Care Corporation during the second quarter worth $230,000. Park Avenue Securities LLC purchased a new position in Fresenius Medical Care Corporation during the second quarter worth $234,000. Finally, Greenleaf Trust purchased a new position in Fresenius Medical Care Corporation during the first quarter worth $205,000. Institutional investors own 2.82% of the company’s stock.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Stock Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related stocks with our FREE daily email newsletter.